Deutschland
India
Lietuva
Search
Search
Search
Looking toward the future of kinases in immunology, the path forward is anything but clear cut. As more next-gen JAK and JAK-adjacent therapies progress toward entering the market, there are a number of challenges that will be key factors in determining the success of these agents.
The potentially bifurcated way in which health authorities in the US and EU may handle JAK safety concerns will have downstream implications in each market. Regulators’ differing approaches will impact line of therapy and require developers to tailor commercial strategies on a per-geography basis to account for differing competitive landscapes and subsequent clinical trial comparators as well as pricing and access strategy.
Complexity demands a trusted guide with the unique expertise and cross-sector versatility to deliver unwavering success. We work with organizations across regulated commercial and public sectors to catalyze transformation and pioneer new directions for the future.